Study, location and reference | Number of Patients | Study Design | Age * (years) | CD4 Cell Count** | Vaccine strains | Â | Comparator |
---|---|---|---|---|---|---|---|
Tasker 1999, USA, [26] | 102 | Randomized double blind, placebo controlled | 33 | 403.1 | A/Johannesburg/33/94 A/Texas/36/91 B/Harbin/07/94) | (H3N2), (HlNl), | Saline |
Fine 2001, USA, [4] | 71 | Outbreak investigation | 38 | 149 | A/Nanchang/933/95(H3N2), A/Texas/36/91(H1N1), B/Harbin/07/94, York/83/97(H3N2) | A/New | None |
Raineri 2005, Italy, [34] | 145 | Prospective nonrandomized | 20–69 | -- | INFLEXAL V, Berna |  | None |
Yamanaka 2005, Japan, [27] | 328 | Prospective nonrandomized | 40.8 | 379 | A/New Caledonia/20/99 A/Panama/2007/99 B/Shanton/7/87 | (H1N1), (H3N2), | None |